Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence

This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon

Inclusion Criteria:

• Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome
• Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician
• Patients using or willing to use the BETACONNECT autoinjector for Betaferon application
• Written informed consent

Exclusion Criteria:

• Patients receiving any other disease modifying drug
• Contraindications of Betaferon described in the Summary of Product Characteristics
• Patients participating in any other clinical or non-interventional study, evaluating MS therapy